1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-Melanoma Skin Cancer Treatment Revenue
1.4 Market by Type
1.4.1 Global Non-Melanoma Skin Cancer Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Radiation Therapy
1.4.4 Photodynamic Therapy
1.5 Market by Application
1.5.1 Global Non-Melanoma Skin Cancer Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Non-Melanoma Skin Cancer Treatment Market Perspective (2015-2026)
2.2 Global Non-Melanoma Skin Cancer Treatment Growth Trends by Regions
2.2.1 Non-Melanoma Skin Cancer Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Non-Melanoma Skin Cancer Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Non-Melanoma Skin Cancer Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Non-Melanoma Skin Cancer Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Non-Melanoma Skin Cancer Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Non-Melanoma Skin Cancer Treatment Players by Market Size
3.1.1 Global Top Non-Melanoma Skin Cancer Treatment Players by Revenue (2015-2020)
3.1.2 Global Non-Melanoma Skin Cancer Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Non-Melanoma Skin Cancer Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Non-Melanoma Skin Cancer Treatment Market Concentration Ratio
3.2.1 Global Non-Melanoma Skin Cancer Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Non-Melanoma Skin Cancer Treatment Revenue in 2019
3.3 Non-Melanoma Skin Cancer Treatment Key Players Head office and Area Served
3.4 Key Players Non-Melanoma Skin Cancer Treatment Product Solution and Service
3.5 Date of Enter into Non-Melanoma Skin Cancer Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Non-Melanoma Skin Cancer Treatment Historic Market Size by Type (2015-2020)
4.2 Global Non-Melanoma Skin Cancer Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)
5.2 Global Non-Melanoma Skin Cancer Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
6.2 Non-Melanoma Skin Cancer Treatment Key Players in North America (2019-2020)
6.3 North America Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
6.4 North America Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
7.2 Non-Melanoma Skin Cancer Treatment Key Players in Europe (2019-2020)
7.3 Europe Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
7.4 Europe Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)
8 China
8.1 China Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
8.2 Non-Melanoma Skin Cancer Treatment Key Players in China (2019-2020)
8.3 China Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
8.4 China Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
9.2 Non-Melanoma Skin Cancer Treatment Key Players in Japan (2019-2020)
9.3 Japan Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
9.4 Japan Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
10.2 Non-Melanoma Skin Cancer Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)
11 India
11.1 India Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
11.2 Non-Melanoma Skin Cancer Treatment Key Players in India (2019-2020)
11.3 India Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
11.4 India Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
12.2 Non-Melanoma Skin Cancer Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
12.4 Central & South America Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Boehringer Ingelheim
13.1.1 Boehringer Ingelheim Company Details
13.1.2 Boehringer Ingelheim Business Overview
13.1.3 Boehringer Ingelheim Non-Melanoma Skin Cancer Treatment Introduction
13.1.4 Boehringer Ingelheim Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020))
13.1.5 Boehringer Ingelheim Recent Development
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Details
13.2.2 Bristol-Myers Squibb Business Overview
13.2.3 Bristol-Myers Squibb Non-Melanoma Skin Cancer Treatment Introduction
13.2.4 Bristol-Myers Squibb Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.2.5 Bristol-Myers Squibb Recent Development
13.3 Eli Lilly
13.3.1 Eli Lilly Company Details
13.3.2 Eli Lilly Business Overview
13.3.3 Eli Lilly Non-Melanoma Skin Cancer Treatment Introduction
13.3.4 Eli Lilly Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.3.5 Eli Lilly Recent Development
13.4 Roche
13.4.1 Roche Company Details
13.4.2 Roche Business Overview
13.4.3 Roche Non-Melanoma Skin Cancer Treatment Introduction
13.4.4 Roche Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.4.5 Roche Recent Development
13.5 Merck
13.5.1 Merck Company Details
13.5.2 Merck Business Overview
13.5.3 Merck Non-Melanoma Skin Cancer Treatment Introduction
13.5.4 Merck Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.5.5 Merck Recent Development
13.6 Novartis
13.6.1 Novartis Company Details
13.6.2 Novartis Business Overview
13.6.3 Novartis Non-Melanoma Skin Cancer Treatment Introduction
13.6.4 Novartis Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.6.5 Novartis Recent Development
13.7 Mylan
13.7.1 Mylan Company Details
13.7.2 Mylan Business Overview
13.7.3 Mylan Non-Melanoma Skin Cancer Treatment Introduction
13.7.4 Mylan Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.7.5 Mylan Recent Development
13.8 Sun Pharmaceutical
13.8.1 Sun Pharmaceutical Company Details
13.8.2 Sun Pharmaceutical Business Overview
13.8.3 Sun Pharmaceutical Non-Melanoma Skin Cancer Treatment Introduction
13.8.4 Sun Pharmaceutical Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.8.5 Sun Pharmaceutical Recent Development
13.9 Almirall
13.9.1 Almirall Company Details
13.9.2 Almirall Business Overview
13.9.3 Almirall Non-Melanoma Skin Cancer Treatment Introduction
13.9.4 Almirall Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.9.5 Almirall Recent Development
13.10 Elekta
13.10.1 Elekta Company Details
13.10.2 Elekta Business Overview
13.10.3 Elekta Non-Melanoma Skin Cancer Treatment Introduction
13.10.4 Elekta Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.10.5 Elekta Recent Development
13.11 Varian Medical Systems
10.11.1 Varian Medical Systems Company Details
10.11.2 Varian Medical Systems Business Overview
10.11.3 Varian Medical Systems Non-Melanoma Skin Cancer Treatment Introduction
10.11.4 Varian Medical Systems Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
10.11.5 Varian Medical Systems Recent Development
13.12 Sensus Healthcare
10.12.1 Sensus Healthcare Company Details
10.12.2 Sensus Healthcare Business Overview
10.12.3 Sensus Healthcare Non-Melanoma Skin Cancer Treatment Introduction
10.12.4 Sensus Healthcare Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
10.12.5 Sensus Healthcare Recent Development
13.13 iCAD
10.13.1 iCAD Company Details
10.13.2 iCAD Business Overview
10.13.3 iCAD Non-Melanoma Skin Cancer Treatment Introduction
10.13.4 iCAD Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
10.13.5 iCAD Recent Development
13.14 Accuray
10.14.1 Accuray Company Details
10.14.2 Accuray Business Overview
10.14.3 Accuray Non-Melanoma Skin Cancer Treatment Introduction
10.14.4 Accuray Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
10.14.5 Accuray Recent Development
13.15 Ion Beam Applications
10.15.1 Ion Beam Applications Company Details
10.15.2 Ion Beam Applications Business Overview
10.15.3 Ion Beam Applications Non-Melanoma Skin Cancer Treatment Introduction
10.15.4 Ion Beam Applications Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
10.15.5 Ion Beam Applications Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
【掲載企業】
Boehringer Ingelheim、Bristol-Myers Squibb、Eli Lilly、Roche、Merck、Novartis、Mylan、Sun Pharmaceutical、Almirall、Elekta、Varian Medical Systems、Sensus Healthcare、iCAD、Accuray、Ion Beam Applications
【免責事項】
https://www.globalresearch.jp/disclaimer